Efficacy of capecitabine and temozolomide regimen in neuroendocrine tumors: Data from the Turkish Oncology Group

Basit Öğe Kaydı
dc.authorid0000-0001-7858-8180en_US
dc.authorid0000-0002-7931-2941en_US
dc.contributor.authorÜnal, Çağlar
dc.contributor.authorAzizy, Abdulmunir
dc.contributor.authorKarabulut, Senem
dc.contributor.authorTaştekin, Didem
dc.contributor.authorAkyıldız, Arif
dc.contributor.authorYaşar, Serkan
dc.contributor.authorKalkan, Ziya
dc.contributor.authorOruç, Zeynep
dc.date.accessioned2024-01-09T06:26:29Z
dc.date.available2024-01-09T06:26:29Z
dc.date.issued2023en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalıen_US
dc.description.abstractINTRODUCTION: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs). METHODS: We conducted a multicenter retrospective study analyzing the data of 308 patients with metastatic NETs treated with CAPTEM between 2010 and 2022 in 34 different hospitals across various regions of Turkey. RESULTS: The median follow-up time was 41.0 months (range: 1.7-212.1), and the median age was 53 years (range: 22-79). Our results across the entire patient cohort showed a median progression-free survival (PFS) of 10.6 months and a median overall survival (OS) of 60.4 months. First-line CAPTEM treatment appeared more effective, with a median PFS of 16.1 months and a median OS of 105.8 months (median PFS 16.1, 7.9, and 9.6 months in first-, second- and ≥third-line respectively, P = .01; with median OS values of 105.8, 47.2, and 24.1 months, respectively, P = .003) In terms of ORR, the first-line treatment again performed better, resulting in an ORR of 54.7% compared to 33.3% and 30.0% in the second and third or higher lines, respectively (P < .001). Grade 3-4 side effects occurred only in 22.5% of the patients, leading to a discontinuation rate of 9.5%. Despite the differences in outcomes based on treatment line, we did not observe a significant difference in terms of side effects between the first and subsequent lines of treatment. CONCLUSIONS AND RELEVANCE: The substantial superior outcomes in patients receiving first-line CAPTEM treatment highlight its potential as an effective treatment strategy for patients with metastatic NET.en_US
dc.identifier.citationÜnal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S. ve diğerleri. (2023). Efficacy of capecitabine and temozolomide regimen in neuroendocrine tumors: Data from the Turkish Oncology Group. The Oncologist, 28(10), 875-884.en_US
dc.identifier.doi10.1093/oncolo/oyad257
dc.identifier.endpage884en_US
dc.identifier.issn1549-490X
dc.identifier.issue10en_US
dc.identifier.pmid37676712
dc.identifier.scopus2-s2.0-85174080160
dc.identifier.scopusqualityQ1
dc.identifier.startpage875en_US
dc.identifier.urihttps://academic.oup.com/oncolo/article/28/10/875/7263101?login=true
dc.identifier.urihttps://hdl.handle.net/11468/13157
dc.identifier.volume28en_US
dc.identifier.wosWOS:001063354900001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKalkan, Ziya
dc.institutionauthorOruç, Zeynep
dc.language.isoenen_US
dc.publisherNLM (Medline)en_US
dc.relation.ispartofThe Oncologist
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCapecitabineen_US
dc.subjectCAPTEMen_US
dc.subjectNeuroendocrine neoplasiaen_US
dc.subjectNeuroendocrine tumorsen_US
dc.subjectTemozolomideen_US
dc.titleEfficacy of capecitabine and temozolomide regimen in neuroendocrine tumors: Data from the Turkish Oncology Groupen_US
dc.titleEfficacy of capecitabine and temozolomide regimen in neuroendocrine tumors: Data from the Turkish Oncology Group
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors.pdf
Boyut:
4.37 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu